Siemens announced it intends to further develop its healthcare business, Siemens Healthineers, and give it even greater flexibility in implementing its growth plans. To this end, the company is planning to publicly list its healthcare business.

November 10, 2016 — A Henry Ford Hospital cardiologist is pioneering a promising new procedure to improve the success of mitral valve replacement.

Interventional cardiologist Adam Greenbaum, M.D., medical co-director of the Center For Structural Heart Disease at Henry Ford Hospital, believes the procedure — slicing a leaflet with an electrified wire through a tiny catheter before replacing a mitral valve — will save thousands of lives.

Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable coagulation analyzer. The Xprecia Stride Coagulation Analyzer delivers fast, reliable Prothrombin Time/International Normalized Ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist.

NeoChord Inc. announced the first use of its DS1000 System in the United States as it enrolled the first patient in the RECHORD Trial.

Current ACCF/AHA guidelines recommend fibrinolysis (FL) as the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) patients with expected delays of > 120 minutes from first medical contact to percutaneous coronary intervention (PCI). The guidelines recommend this be followed by transfer to a PCI center with angiography/PCI within 3-24 hours. However, assessment of reperfusion prior to angiography may not be accurate based on clinical and electrocardiogram (ECG) criteria alone. Recent data suggested increased recurrent ischemic events within the first 24 hours. The aim of this study, which was conducted from 2003-2015, was to assess the safety of very early PCI (< 3 hours) following FL.

The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having a potentially lethal heart rhythm condition. This erroneous diagnosis occurred as a result of inappropriate use of genetic testing and incorrect interpretation of genetic test results, according to Mayo Clinic research published in Mayo Clinic Proceedings.

November 9, 2016 — Merit Medical Systems Inc. announced that it has received 510(k) clearance for the SwiftNINJA Steerable Microcatheter. The clearance covers peripheral and coronary applications. With the exception of Japan, Merit has global distribution rights for the SwiftNINJA.

November 9, 2016 — A pioneering way to access the heart for transcatheter valve replacement has a 98 percent success rate, according to a study published in the Journal of the American College of Cardiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now